Resultados da pesquisa - safety after failed phase 1

Pesquisas alternativas:
failed phase » failed case (Expandir a Pesquisa), labeled phase (Expandir a Pesquisa), enabled phase (Expandir a Pesquisa)
phase 1 » phase _ (Expandir a Pesquisa), phase 2 (Expandir a Pesquisa)

21

Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

Por Bégin, Philippe, Dominguez, Tina, Wilson, Shruti P, Bacal, Liane, Mehrotra, Anjuli, Kausch, Bethany, Trela, Anthony, Tavassoli, Morvarid, Hoyte, Elisabeth, O’Riordan, Gerri, Blakemore, Alanna, Seki, Scott, Hamilton, Robert G, Nadeau, Kari C
Publicado em 2014

“... protein. OBJECTIVE: To evaluate the safety and dose tolerability of a Phase 1 Single Site OIT protocol...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

22

Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine

Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic...

Por Lee, Choong-kun, Jung, Minkyu, Choi, Hye Jin, Kim, Hye Ryun, Kim, Hyo Song, Roh, Mi Ryung, Ahn, Joong Bae, Chung, Hyun Cheol, Heo, Su Jin, Rha, Sun Young, Shin, Sang Joon
Publicado no Cancer Res Treat (2015)

“... progression after first-line chemotherapy, and platinum-alkylating agents combined with paclitaxel have shown...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

23

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom...

Por van de Putte, L B A, Atkins, C, Malaise, M, Sany, J, Russell, A, van Riel, P L C M, Settas, L, Bijlsma, J, Todesco, S, Dougados, M, Nash, P, Emery, P, Walter, N, Kaul, M, Fischkoff, S, Kupper, H
Publicado em 2004

“...Objective: To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

24

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection...

Por Gane, Edward J., DeJesus, Edwin, Janczewska, Ewa, George, Jacob, Diago, Moises, Da Silva, Mariliza Hendrique, Reesink, Henk, Nikitin, Igor, Hinrichsen, Holger, Bourgeois, Stefan, Ferenci, Peter, Shukla, Umesh, Kalmeijer, Ronald, Lenz, Oliver, Fevery, Bart, Corbett, Chris, Beumont, Maria, Jessner, Wolfgang
Publicado no BMC Infect Dis (2017)

“... and Phase 1 group). The primary endpoint was sustained virologic response 12 weeks after planned end...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

25

$Phase 1 study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies$

Phase 1 study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies

Por Bachanova, Veronika, Frankel, Arthur E., Cao, Qing, Lewis, Dixie, Grzywacz, Bartosz, Verneris, Michael R., Ustun, Celalettin, Lazaryan, Aleksandr, McClune, Brian, Warlick, Erica D., Kantarjian, Hagop, Weisdorf, Daniel J., Miller, Jeffrey S., Vallera, Daniel A.
Publicado no Clin Cancer Res (2015)

“... 1 dose escalation study to assess the safety, maximum tolerated dose (MTD), and preliminary efficacy...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

26

Preoperative chemoradiotherapy using S-1 combined with celecoxib for advanced lower rectal cancer: Phase I/II study

Preoperative chemoradiotherapy using S-1 combined with celecoxib for advanced lower rectal cancer: Phase I/II study

Por Ohira, Gaku, Miyauchi, Hideaki, Hayano, Koichi, Imanishi, Shunsuke, Tochigi, Toru, Maruyama, Tetsuro, Hanaoka, Toshiharu, Okada, Koichiro, Kobayashi, Hiroki, Uno, Takashi, Matsubara, Hisahiro
Publicado no J Anus Rectum Colon (2019)

“... of celecoxib was set at 400 mg/day. In Phase I, the S-1 dose was started at 80 mg/m(2)/day; in Phase II, S-1...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

27

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

Por Trojan, Jörg, Waidmann, Oliver
Publicado no J Hepatocell Carcinoma (2016)

“... of the RESORCE trial, a placebo-controlled Phase III study that evaluated the efficacy and safety of regorafenib...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

28

Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial

Investigated the safety of intra-renal arterial transfusion of autologous CD34+ cells and time courses of creatinine levels, endothelial dysfunction biomarkers and micro-RNAs in chronic kidney disease patients-phase I clinical trial

Por Lee, Mel S., Lee, Fan-Yen, Chen, Yung-Lung, Sung, Pei-Hsun, Chiang, Hsin-Ju, Chen, Kuan-Hung, Huang, Tien-Hung, Chen, Yi-Ling, Chiang, John Y., Yin, Tsung-Cheng, Chang, Hsueh-Wen, Yip, Hon-Kan
Publicado no Oncotarget (2017)

“...This was a phase I clinical trial to investigate the safety of autologous peripheral-blood-derived...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

29

ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

Por Gilbert, Mark, Zhang, Peixin, Sloan, Andrew, Aldape, Kenneth, Wu, Jing, Rogers, Lisa, Wen, Patrick, Barani, Igor, Iwamoto, Fabio, Raval, Raju, Voloshin, Alfredo, de Groot, John, Won, Minhee, Mehta, Minesh P
Publicado no Neuro Oncol (2018)

“...). This study evaluated the safety of anti-CTLA-4 (IPI) and anti-PD-1 (NIVO) ICIs alone or in combination...”
Obter o texto integral
Obter o texto integral

Artigo

30

Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine vs. standard-dose intramuscular vaccine in HIV-1-infected adults

Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine vs. standard-dose intramuscular vaccine in HIV-1-infected adults

Por Ansaldi, Filippo, Valle, Laura, de Florentiis, Daniela, Parodi, Valentina, Murdaca, Giuseppe, Bruzzone, Bianca M., Durando, Paolo, Setti, Maurizio, Icardi, Giancarlo
Publicado em 2012

“... to assess the antibody response at one month and 3 mo after vaccination. Both vaccines showed optimal safety...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

31

ERS Special Article. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial

ERS Special Article. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial

Por Velásquez, Gustavo E., Brooks, Meredith B., Coit, Julia M., Pertinez, Henry, Vargas Vásquez, Dante, Sánchez Garavito, Epifanio, Calderón, Roger I., Jiménez, Judith, Tintaya, Karen, Peloquin, Charles A., Osso, Elna, Tierney, Dylan B., Seung, Kwonjune J., Lecca, Leonid, Davies, Geraint R., Mitnick, Carole D.
Publicado no Am J Respir Crit Care Med (2018)

“... (P = 0.7092) up to 4 weeks after the intensive phase. Treatment failed or disease recurred in 11...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

32

Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma

Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma

Por Redman, Bruce G., Chang, Alfred E., Whitfield, Joel, Esper, Peg, Jiang, Guihua, Braun, Thomas, Roessler, Blake, Mulé, James J
Publicado em 2008

“...Twenty four subjects with metastatic melanoma were treated on a randomized Phase Ib trial...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

33

Endoscopic treatment of esophageal fistulas after esophagectomy with injection of an alpha-cyanoacrylate monomer: a phase II study

Endoscopic treatment of esophageal fistulas after esophagectomy with injection of an alpha-cyanoacrylate monomer: a phase II study

Por Ojima, Toshiyasu, Nakamura, Masaki, Nakamori, Mikihito, Katsuda, Masahiro, Hayata, Keiji, Tsuji, Toshiaki, Maruoka, Shimpei, Yamaue, Hiroki
Publicado no Endosc Int Open (2018)

“... than 1 wk of conservative medical treatment for intractable esophageal fistulas after esophagectomy...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

34

Phase I Study of Ruxolitinib in Previously Treated Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome with Evidence of NF-kB Activation

Phase I Study of Ruxolitinib in Previously Treated Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome with Evidence of NF-kB Activation

Por Abaza, Yasmin, Hidalgo-Lopez, Juliana E., Verstovsek, Srdan, Jabbour, Elias, Ravandi, Farhad, Borthakur, Gautam, Estrov, Zeev, Alvarado, Yesid, Burger, Jan, Schneider, Heather, Soltysiak, Kelly A., Wei, Yue, Kantarjian, Hagop M., Bueso-Ramos, Carlos E., Garcia-Manero, Guillermo
Publicado no Leuk Res (2018)

“... ruxolitinib, a JAK1/JAK2 inhibitor, suppresses NF-kB expression, we conducted a phase 1 dose-escalation study...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

35

Minimally invasive versus open pancreatoduodenectomy (LEOPARD-2): study protocol for a randomized controlled trial

Minimally invasive versus open pancreatoduodenectomy (LEOPARD-2): study protocol for a randomized controlled trial

Por de Rooij, Thijs, van Hilst, Jony, Bosscha, Koop, Dijkgraaf, Marcel G., Gerhards, Michael F., Groot Koerkamp, Bas, Hagendoorn, Jeroen, de Hingh, Ignace H., Karsten, Tom M., Lips, Daan J., Luyer, Misha D., Molenaar, I. Quintus, van Santvoort, Hjalmar C., Tran, T. C. Khé, Busch, Olivier R., Festen, Sebastiaan, Besselink, Marc G.
Publicado no Trials (2018)

“... in an enhanced recovery setting. After the first 40 patients (phase 2), the data safety monitoring board...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

36

Earlier Endpoints Are Required for Hemorrhagic Shock Trials among Severely Injured Patients

Earlier Endpoints Are Required for Hemorrhagic Shock Trials among Severely Injured Patients

Por Fox, Erin E., Holcomb, John B., Wade, Charles E., Bulger, Eileen M., Tilley, Barbara C.
Publicado no Shock (2017)

“... due to traumatic injury decreases rapidly after enrollment from 4.6% per hour at 1 hour post...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

37

Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer

Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer

Por Degiuli, M, Sasako, M, Ponti, A, Calvo, F
Publicado em 2004

“... and mortality. Following these results, we started a phase II trial to evaluate the safety and efficacy...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

38

Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study

Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza...

Por Lee, Jin, Lee, Kyung-Yil, Kim, Jong-Hyun, Kim, Chun Soo, Eun, Byung Wook, Kim, Hwang Min, Kim, Dong Ho, Hong, Young Jin, Choi, Young Youn, Jo, Dae Sun, Ma, Sang Hyuk, Kang, Jin Han
Publicado no J Korean Med Sci (2018)

“... beginning in the 2013–2014 flu season. This study was conducted to evaluate the immunogenicity and safety...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

39

$Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer$

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets...

Por Trarbach, T, Moehler, M, Heinemann, V, Köhne, C-H, Przyborek, M, Schulz, C, Sneller, V, Gallant, G, Kanzler, S
Publicado em 2010

“... (TRAIL-R1). METHODS: This phase II multicentre study was designed to evaluate the efficacy and safety...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

40

$Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis$

Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis

Por Mross, Klaus, Büchert, Martin, Frost, Annette, Medinger, Michael, Stopfer, Peter, Studeny, Matus, Kaiser, Rolf
Publicado em 2014

“... signalling, as well as RET and Flt3. The maximum tolerated dose of nintedanib was evaluated in a phase I...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

[1]
Anterior
1
2
3
4
5
6
7
8
9
10
Seguinte
[10]